Kiromic Biopharma Inc (KRBP)

NASDAQ
Currency in USD
Disclaimer
3.040
-0.300
(-8.98%)
Closed
3.070
+0.030
(+0.987%)
After Hours
Real-time Data
Day's Range
2.960
3.376
52 wk Range
2.590
22.800
Volume
83,171
Prev. Close
3.34
Open
3.27
Day's Range
2.96-3.376
52 wk Range
2.59-22.8
Volume
83,171
Average Volume (3m)
349,052
1-Year Change
-80.88%
Shares Outstanding
979,243
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

Kiromic Biopharma Inc News

Kiromic Biopharma Inc Company Profile

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.